Department of medicine, Inova Fairfax Hospital
Gastroenterology
Dr. Zobair Younossi, MD
|
|
Give Review
Zobair Younossi works in the field of Gastroenterology. He researched medicine at University of Rochester School of Medicine and Dentistry. He received awards:"America's Top Doctors", "Top Doctors:Washington DC Area", "Top Doctors:Washington-Baltimore", "Fellow (AGAF)", "Fellow (FACG)" and "Super Doctor". Zobair Younossi, MD is a published physician. He published 78 publications, including: 'Epidemiology and natural history of non-alcoholic fatty liver disease.' He is registered with Medicare.
Publications
- A meta-analytic assessment of the risk of chronic kidney Disease in patients with chronic hepatitis C virus infection.
- Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage.
- Impact of eradicating Hepatitis C virus on the work productivity of chronic Hepatitis C (CH-C) patients: an economic model from five European countries.
- Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009.
- Effects of Viral Eradication with Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients with Chronic HCV Infection.
- Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver Disease?
- Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
- Nonalcoholic steatohepatitis is the second leading etiology of liver Disease among adults awaiting liver transplantation in the United States.
- Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver Disease and new treatment regimens.
- Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic Hepatitis C virus genotype 1 infection.
- Editorial: The association of Hepatitis C virus infection and post-liver transplant diabetes - authors' reply.
- Improvement of health-related quality of life and work productivity in chronic Hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosb...
- Resource utilization and survival among Medicare patients with advanced liver Disease.
- Ledipasvir/sofosbuvir regimens for chronic Hepatitis C infection: Insights from a work productivity economic model from the United States.
- A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic Hepatitis C virus genotype 4 infection.
- The outcomes of adult liver transplants in the United States from 1987 to 2013.
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
- The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic Hepatitis C.
- Anti-Adipocyte Antibody Response in Patients with Non Alcoholic Fatty Liver Disease.
- The association of Hepatitis C virus infection and post-liver transplant diabetes: data from 17Â 000 HCV-infected transplant recipients.
- Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Authors' reply.
- Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 Hepatitis C? Authors' reply.
- Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic Hepatitis C virus genotype 1 infection.
- Hepatitis: Chronic HCV infection, diabetes and liver-related outcomes.
- A Single Non-invasive Model to Diagnose Non-alcoholic Fatty Liver Disease (NAFLD)and Non-alcoholic Steatohepatitis (NASH).
- Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic Hepatitis C treated with sofosbuvir regimens.
- The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85Â 000 liver transplant recipients in the US.
- The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013.
- Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature.
- Sofosbuvir (Sovaldi) for the treatment of Hepatitis C.
- Inpatient resource utilization, Disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.
- Reply to: Cost-effectiveness of upcoming treatments for Hepatitis C: we need to get the models right.
- Patient-reported outcomes in chronic hepatitis C patients with Cirrhosis treated with sofosbuvir-containing regimens.
- Patient-Reported Outcomes Assessment in Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin: The VALENCE Study.
- Adipocytokine Expression Associated with miRNA Regulation and Diagnosis of NASH in Obese Patients with NAFLD.
- The impact of Hepatitis C burden: an evidence-based approach.
- Monitoring and treatment of inactive chronic Hepatitis B: Is it Cost Effective?
- Obesity and liver Disease.
- Host genetic variants in obesity-related nonalcoholic Fatty liver Disease.
- Multiple Factors Predict Physical Performance in People with Chronic Liver Disease.
- Systematic review with meta-analysis: non-alcoholic steatoHepatitis - a case for personalised treatment based on pathogenic targets.
- Minimal Impact of Sofosbuvir and Ribavirin on Health Related Quality of Life in Chronic Hepatitis C (CH-C).
- Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic Hepatitis C in the REALIZE trial.
- A New Comorbidity Model for Predicting Mortality in Patients With Cirrhosis: Does It Work?
- Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients.
- Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
- The impact of chronic Hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010.
- Inpatient Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United States Data from 2005 to 2009.
- Mortality associated with alcohol-related liver Disease.
- Commentary: durability of SVR in chronic Hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral.
- Expression of genes for miRNAs-processing enzymes is altered in advanced non-alcoholic fatty liver Disease (NAFLD).
- Knowledge about infection is the only predictor of treatment in patients with chronic Hepatitis C.
- Interaction of Type 2 diabetes and nonalcoholic fatty liver Disease.
- Commentary: phlebotomy in non-alcoholic fatty liver Disease.
- Chronic Hepatitis c, genotype 1 in the era of direct antiviral agents: Is it time to skip the biopsy and treat everyone?
- The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: Analysis of the US nationwide inpatient sample.
- Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic Fatty liver Disease.
- Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic Hepatitis C.
- Recent Trends in Inpatient Mortality and Resource Utilization for Patients with Stroke in the United States: 2005-2009.
- In patients with non-alcoholic fatty liver Disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
- Associations of chronic Hepatitis C with metabolic and cardiac outcomes.
- Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example.
- Association of chronic liver Disease with depression: a population-based study.
- Quality of life in Cirrhosis.
- Early gene expression profiles of patients with chronic Hepatitis C treated with pegylated interferon-alfa and ribavirin.
- Nonalcoholic fatty liver Disease: a manifestation of the metabolic syndrome.
- Survey of health status, nutrition and geography of food selection of chronic liver Disease patients.
- Clinical outcomes and resource utilisation in Medicare patients with chronic liver Disease: a historical cohort study.
- Statin use is not associated with liver related mortality.
- Predictors of chronic liver Disease in individuals with human immunodeficiency virus infection.
- Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD.
- Association of work productivity with clinical and patient-reported factors in patients infected with Hepatitis C virus.
- Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial.
- Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
- Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
- Extra-Hepatic Manifestations of Hepatitis C-a Meta-Analysis of Prevalence, Quality of Life, and Economic Burden.
- Epidemiology and natural history of non-alcoholic fatty liver Disease.
Schools
University Of Rochester
Scripps Clinic and Research Foundation
Conditions Treated
- Anemia
- Biliary Atresia
- Cirrhosis
- Esophageal Varices
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:Washington DC Area
- Top Doctors:Washington-Baltimore
- Fellow (AGAF)
- Fellow (FACG)
- Super Doctor
Education
-
Scripps Clinic -
University of Rochester School of Medicine and Dentistry
Hospital
-
Inova Fairfax Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194760298 |
| Last Name Of The Provider | YOUNOSSI |
| First Name Of The Provider | ZOBAIR |
| View All |
Similar Doctors
|
|
Dr. Brian J. Swansiger, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James N. Cooper, MD |
|
|
Dr. Maurice N. Atiyeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert W. Sjogren Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley D. Drake, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashmi A. Tadiparthi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ali Fazel, MD |